Thais Basili

Thais Basili

Auto-generated profile, based on publicly available information

Thais Basili

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FGFelipe C. Geyer
Felipe C. Geyer
ALAnqi Li
Anqi Li
APAnastasios D. Papanastasiou
Anastasios D. Papanastasiou
ASAlison Smith
Alison Smith
PSPier Selenica
Pier Selenica
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Adenomyoepithelioma of the breast is a rare tumor characterized by epithelial−myoepithelial differentiation, whose genetic underpinning is largely unknown. Here we show through whole-exome and targeted massively parallel sequencing analysis that whilst estrogen receptor (ER)-positive adenomyoepitheliomas display PIK3CA or AKT1 activating mutations, ER-negative adenomyoepitheliomas harbor highly recurrent codon Q61 HRAS hotspot mutations, which co-occur with PIK3CA or PIK3R1 mutations. In two- and three-dimensional cell culture models, forced expression of HRASQ61R in non-malignant ER-negative breast epithelial cells with or without a PIK3CAH1047R somatic knock-in results in transformation and the acquisition of the cardinal features of adenomyoepitheliomas, including the expression of myoepithelial markers, a reduction in E-cadherin expression, and an increase in AKT signaling. Our results demonstrate that adenomyoepitheliomas are genetically heterogeneous, and qualify mutations in HRAS, a gene whose mutations are vanishingly rare in common-type breast cancers, as likely drivers of ER-negative adenomyoepitheliomas.

30 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FPFresia Pareja
Fresia Pareja
ABAlissa H. Brandes
Alissa H. Brandes
TBThais Basili
Thais Basili
PSPier Selenica
Pier Selenica
FGFelipe C. Geyer
Felipe C. Geyer
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Granular cell tumors (GCTs) are rare tumors that can arise in multiple anatomical locations, and are characterized by abundant intracytoplasmic granules. The genetic drivers of GCTs are currently unknown. Here, we apply whole-exome sequencing and targeted sequencing analysis to reveal mutually exclusive, clonal, inactivating somatic mutations in the endosomal pH regulatorsATP6AP1orATP6AP2in 72% of GCTs. Silencing of these genes in vitro results in impaired vesicle acidification, redistribution of endosomal compartments, and accumulation of intracytoplasmic granules, recapitulating the cardinal phenotypic characteristics of GCTs and providing a novel genotypic–phenotypic correlation. In addition, depletion of ATP6AP1 or ATP6AP2 results in the acquisition of oncogenic properties. Our results demonstrate that inactivating mutations ofATP6AP1andATP6AP2are likely oncogenic drivers of GCTs and underpin the genesis of the intracytoplasmic granules that characterize them, providing a genetic link between endosomal pH regulation and tumorigenesis.

15 December 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SCSarah Chiang
Sarah Chiang
BWBritta Weigelt
Britta Weigelt
HWHuei-Chi Wen
Huei-Chi Wen
FPFresia Pareja
Fresia Pareja
ARAshwini Raghavendra
Ashwini Raghavendra
SSStuart J. Schnitt
Stuart J. Schnitt
Solid papillary carcinoma with reverse polarity (SPCRP) is a rare breast cancer subtype with an obscure etiology. In this study, we sought to describe its unique histopathologic features and to identify the genetic alterations that underpin SPCRP using massively parallel whole-exome and targeted sequencing. The morphologic and immunohistochemical features of SPCRP support the invasive nature of this subtype. Ten of 13 (77%) SPCRPs harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displayed concurrent pathogenic mutations affecting PIK3CA or PIK3R1. One of the IDH2 wild-type SPCRPs harbored a TET2 Q548* truncating mutation coupled with a PIK3CA H1047R hotspot mutation. Functional studies demonstrated that IDH2 and PIK3CA hotspot mutations are likely drivers of SPCRP, resulting in its reversed nuclear polarization phenotype. Our results offer a molecular definition of SPCRP as a distinct breast cancer subtype. Concurrent IDH2 and PIK3CA mutations may help diagnose SPCRP and possibly direct effective treatment. Cancer Res; 76(24); 7118–29. ©2016 AACR.

4 July 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
Caterina MarchiòCaterina Marchiò
Caterina Marchiò
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
RGRodrigo Gularte-Merida
Rodrigo Gularte-Merida
TBThais Basili
Thais Basili
ABAlissa Brandes
Alissa Brandes
MPMauro Papotti
Mauro Papotti

30 March 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
JLJohn R Lozada
John R Lozada
TBThais Basili
Thais Basili
FPFresia Pareja
Fresia Pareja
BABarbara Alemar
Barbara Alemar
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
FGFelipe C Geyer
Felipe C Geyer

2 January 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
FPFresia Pareja
Fresia Pareja
ESEdaise M. da Silva
Edaise M. da Silva
DFDenise Frosina
Denise Frosina
FGFelipe C. Geyer
Felipe C. Geyer
JLJohn R. Lozada
John R. Lozada
EBEdi Brogi
Edi Brogi